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ABSTRACT

Disclosed herein are motuporamine mimic agents and methods of making and using same. Particularly exemplified are
motuporamine mimic agents comprising cytotoxic activity
and/or anti-metaplastic activity.
3 Claims, 5 Drawing Sheets
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MOTUPORAMINE MIMIC AGENTS

Certain MMA embodiments; of the subject invention such
as, but not limited to, compounds 7 a, 7b, 12 and 14, are more
readily synthesized via synthesis schemes of the subject
invention, including schemes 1 and 2 shown in FIGS. 2 and 3,
respectively. Not being held to any particular theory, it is the
inventors belief that the large anthracene ring system can
substitute (and behave biologically) like the 15-membered
ring of 4a. Alternate embodiments of the subject invention
include, but are not limited to, 14b 17, 18, 19, 20, 21, as
synthesized according to scheme 3 (FIG. 4) and compounds
22, 23, and 24 as synthesized according to scheme 4 (FIG. 5.
Furthermore, other embodiments of the subject invention pertain to the synthesis processes disclosed in FIGS. 2-5, or
portions thereof.
Certain MMA embodiments of the subject invention, such
as, but not limited to 7a, 7b, 12 and 14 not only are good
anticancer agents via their cytotoxic properties, but they also
serve as anti-metastatic agents which block the spread of
cancer cells (a common problem encountered with cancer
patients). A non-toxic anti-metastatic agent would also be of
use to cancer patients because it could be taken as a cancer
preventative and/or as an anti-metastatic agent along with a
different chemotherapeutic regimen. Accordingly, cytotoxic
agents like 7a are helpful toward halting the spread of cancer
as well as killing cancer cells.
In a specific embodiment, MMAs according to the subject
invention comprise the following structure:

CROSS-REFERENCE TO RELATED
APPLICATIONS
5

This application is related to a U.S. Provisional Application of the same title and Applicant name filed Mar. 13, 2006,
and assigned Ser. No. 60/781,963 to which priority is claimed
under 35 USC §119(e).
10

BACKGROUND
The nonselective delivery of drugs to both targeted tumor
cells and healthy cells is a major shortcoming of current
chemotherapies. Enhanced cell targeting during drug delivery could diminish nonspecific toxicities by reducing uptake
by healthy cells. Using existing cellular transporters for drug
delivery provides opportunities for molecular recognition
events to assist in the cell targeting process.
Ever since the published report of the discovery of motuporamines (see 1-3 FIG. 1), naturally occurring anti-cancer
agents, found off the coast (Motupore Island) of new Guinea,
the molecular structure and their bio-functions have fascinated biochemists (Williams et al., J. Org Chem 1998,
63:4838:4841; Williams et al., J. Org. Chem 2002, 67:245248; Roskelley et al., Cancer Res. 2001, 61:6788-6794).
Indeed, In light of the difficulty and expense ofobtaining and
purifying natural motuporamines, efforts have been made
toward developing analogous compounds having similar or
better characteristics that may be synthetically manufactured.
Dihydromotuporamine C, (see 4a, FIG. 1) comprises a fifteen-membered ring, which is difficult to synthesize unless
one uses expensive metal catalysts like Grubb's catalyst.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows structures of motuporamine mimic agents.
FIG. 2 shows a scheme for synthesizing motuporamine
mimic agents.
FIG. 3. shows a scheme for synthesizing motuporamine
mimic agents.
FIG. 4 shows a scheme for synthesizing motuporamine
mimic agents.
FIG. 5 shows a scheme for synthesizing motuporamine
mimic agents.
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DETAILED DESCRIPTION
The invention pertains to motuporamine mimic agents
(MMA) and synthesis thereof that are cytotoxic to cancer
cells and optionally also inhibit their spread to other tissues
(i.e., their metastatic behavior). The invention is based in part
on the inventors' realization that less costly and easily synthesized motuporamine mimic agents are needed and desired.
According to one aspect, the subject invention pertains to
MMAs that have similar biological potency as compound 4a
(see FIG. 1), yet are much easier to synthesize and provide a
cost-efficient entry into this novel drug class. It is difficult
chemically to synthesize 4a. There are several reports (Goldring, W. P. D.; Weiler, L. Cytotoxic Alkaloids Motuporamines
A-C: Synthesis and Structural Verification, Org. Letters 1999,
1(9); 1471-1473; Furstner, A.; Rumbo, A. Ring-Closing
Alkyne Metathesis. Stereoselective Synthesis of the Cytotoxic Marine Alkaloid Motuporamine C, J. Org. Chem. 2000,
65(8); 2608-2611 ), which synthesize 4a through lengthy synthesis steps involving expensive metal catalysts.
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where R is alkylaryl (wherein the aryl ring is either a benzene,
naphthalene, anthracene or pyrene ring system and the alkyl
chain length is either methylene, ethylene, propylene, butylene, pentylene orhexylene), alkyl, cycloalkyl;
R 1 is either hydrogen or linear alkyl (methyl, ethyl, propyl,
butyl, pentyl or hexyl) or branched alkyl (isopropyl, isobutyl,
sec-butyl or t-butyl), or alkylaryl (wherein the aryl ring is
either a benzene, naphthalene, anthracene or pyrene ring system and the alkyl chain length is either methylene, ethylene,
propylene, butylene, pentylene or hexylene ),
R 2 is either hydrogen, alkyl, alkylaryl or aryl or equivalent
to the -(CH2)yR3
R 3 is either hydrogen (H), or hydroxy (-OH), or alkoxy
(-0-alkyl) or alkylamido (-NHCOalkyl), amino (-NH2)
or amino alkyl (-NH-alkyl), or N-alkyl, N-alkylamido, or
Nalkylaryl,N-alkyl amino, x=l-16 and y=l-16 and pharmaceutically relevant inorganic salts thereof. MMA agents
include pharmaceutically acceptable inorganic salts of the
MMA agents (e.g., trihydrochloride salt, 3 HCl salt of skeleton 1). Other embodiments of the subject invention pertain to
methods of synthesizing MMA agents.
Certain preferred MMA embodiments include the following:
1: R=anthracen-9-ylmethyl, R 1 =ethyl, R 2 =H, R 3 =NH2,
x=3, and y=3
2: R=anthracen-9-ylmethyl, R 1 =ethyl, R 2 =H, R 3 =NH2,
x=4, and y=4
3: R=anthracen-9-ylmethyl, R 1 =ethyl, R 2 =H, R 3 =0H,
x=3, and y=3
4:
R=anthracen-9-ylmethyl,
R 1 =ethyl,
R 3 =NHCOCH3, x=3, and y=3

US 7,728,041 B2
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5:
R=anthracen-9-ylmethyl,
R 1 =ethyl,
R 3 =0CH2CH3, x=3, and y=3
6: R=anthracen-9-ylmethyl, R 1 =H, R 2 =H, R 3 =NH2, x=3,
andy=3
7:
R=anthracen-9-ylmethyl,
R 3 =NHBOC, x=3, and y=3
8:
R=anthracen-9-ylmethyl,
R 1 =ethyl,
R 3 =NHBOC, x=3, and y=3
9:
R=anthracen-9-ylmethyl,
R 3 =NHBOC, x=4, and y=4
10: R=anthracen-9-ylmethyl, R 1 =ethyl, R 2 =BOC,
R 3 =NHBOC, x=4, and y=4
11:
R=anthracen-9-ylmethyl,
R 1 =ethyl,
R 2 =H,
R 3 =NHCOR4 , where R4 is linear or branched alkyl, aryl or
alkylaryl, x=3, and y=3
In an alternative embodiment, MMAs according to the
subject invention comprise the following structure:

therapeutic effect, e.g., cytotoxicity of cancer cells in a subject and/or metastatic behavior. Pharmaceutical compositions
of the invention can comprise, for example, a Motuporamine
Mimic Agent (MMA). The compositions can be administered
alone or in combination with at least one other agent, such as
stabilizing compound, which can be administered in any sterile, biocompatible pharmaceutical carrier, including, but not
limited to, saline, buffered saline, dextrose, and water. The
compositions can be administered to a patient alone, or in
combination with other agents, drugs or hormones.
In addition to the active ingredients, these pharmaceutical
compositions can contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which
facilitate processing of the active compounds into preparations which can be used pharmaceutically. Pharmaceutical
compositions of the invention can be administered by any
number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, parenteral, topical, sublingual, or rectal
means. Pharmaceutical compositions for oral administration
can be formulated using pharmaceutically acceptable carriers
well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to
be formulated as tablets, pills, dragees, capsules, liquids, gels,
syrups, slurries, suspensions, and the like, for ingestion by the
patient.
Pharmaceutical preparations for oral use can be obtained
through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing
the mixture of granules, after adding suitable auxiliaries, if
desired, to obtain tablets or dragee cores. Suitable excipients
are carbohydrate or protein fillers, such as sugars, including
lactose, sucrose, mannitol, or sorbitol; starch from com,
wheat, rice, potato, or other plants; cellulose, such as methyl
cellulose, hydroxypropylmethylcellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth;
and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents can be added, such as the crosslinked polyvinyl pyrrolidone, agar, alginic acid, or a salt
thereof, such as sodium alginate.
Dragee cores can be used in conjunction with suitable
coatings, such as concentrated sugar solutions, which also
can contain gum arabic, talc, polyvinylpyrrolidone, carbopol
gel, polyethylene glycol, and/or titanium dioxide, lacquer
solutions, and suitable organic solvents or solvent mixtures.
Dyestuffs or pigments can be added to the tablets or dragee
coatings for product identification or to characterize the quantity of active compound, i.e., dosage.
Pharmaceutical preparations which can be used orally
include push fit capsules made of gelatin, as well as soft,
sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches,
lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be
dissolved or suspended in suitable liquids, such as fatty oils,
liquid, or liquid polyethylene glycol with or without stabilizers.
Pharmaceutical formulations suitable for parenteral
administration can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks'
solution, Ringer's solution, or physiologically buffered
saline. Aqueous injection suspensions can contain substances
which increase the viscosity of the suspension, such as
sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds can be pre-

10
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Formula II 20

13: R=anthracen-9-ylmethyl, R 1 =ethyl, R 2 =H, R 3 =H, x=3
14: R=anthracen-9-ylmethyl, R 1 =ethyl, R 2 =H, R 3 =BOC
(t-butylcarbonyloxy), x=3
15: R=anthracen-9-ylmethyl, R 1 =H, R 2 =H, R 3 =H, x=3
16: R=anthracen-9-ylmethyl, R 1 =H, R 2 =H, R 3 =BOC
(t-butylcarbonyloxy), x=3
In an alternative embodiment, MMAs according to the
subject invention comprise the following structure:

Formula III
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17: R=anthracen-9-ylmethyl, R 1 =ethyl, R 2 =H, x=3
18: R=anthracen-9-ylmethyl, R 1 =H, R 2 =H, x=3
The following structures are those referred to in the formulas above:
45
Formula IV

50

55
anthracen-9-ylmethyl
Formula V

60
tert-butylcarbonyloxy (BOC group)

Pharmaceutical Compositions
The invention also pertains to pharmaceutical compositions which can be administered to a patient to achieve a

65
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pared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame
oil, or synthetic fatty acid esters, such as ethyl oleate or
triglycerides, or liposomes. Non-lipid polycationic amino
polymers also can be used for delivery. Optionally, the suspension also can contain suitable stabilizers or agents which
increase the solubility of the compounds to allow for the
preparation of highly concentrated solutions. For topical or
nasal administration, penetrants appropriate to the particular
barrier to be permeated are used in the formulation. Such
penetrants are generally known in the art.
The pharmaceutical compositions of the present invention
can be manufactured in a manner that is known in the art, e.g.,
by means of conventional mixing, dissolving, granulating,
dragee making, levigating, emulsifying, encapsulating,
entrapping, or lyophilizing processes. The pharmaceutical
composition can be provided as a salt and can be formed with
many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be
more soluble in aqueous or other protonic solvents than are
the corresponding free base forms. In other cases, the preferred preparation can be a lyophilized powder which can
contain any or all of the following: 150 mM histidine, 0.1 %
2% sucrose, and 27% mannitol, at a pH range of 4.5 to 5.5,
that is combined with buffer prior to use.
In one embodiment, the reagent is delivered using a liposome. Preferably, the liposome is stable in the animal into
which it has been administered for at least about 30 minutes,
more preferably for at least about 1 hour, and even more
preferably for at least about 24 hours. A liposome comprises
a lipid composition that is capable of targeting a reagent,
particularly a polynucleotide, to a particular site in an animal,
such as a human. Preferably, the lipid composition of the
liposome is capable of targeting to a specific organ of an
animal, such as the lung, liver, spleen, heart brain, lymph
nodes, and skin.
A liposome useful in the present invention comprises a
lipid composition that is capable of fusing with the plasma
membrane of the targeted cell to deliver its contents to the
cell. Preferably, the transfection efficiency of a liposome is
about 0.5 µg of DNA per 16 nmole of liposome delivered to
about 106 cells, more preferably about 1.0 µg of DNA per 16
nmole ofliposome delivered to about 106 cells, and even more
preferably about 2.0 µg of DNA per 16 nmol of liposome
delivered to about 10 6 cells. Preferably, a liposome is between
about 100 and 500 nm, more preferably between about 150
and 450 nm, and even more preferably between about 200 and
400 nm in diameter.
Suitable liposomes for use in the present invention include
those liposomes standardly used in, for example, gene delivery methods known to those of skill in the art. More preferred
liposomes include liposomes having a polycationic lipid
composition and/or liposomes having a cholesterol backbone
conjugated to polyethylene glycol. Optionally, a liposome
comprises a compound capable of targeting the liposome to a
particular cell type, such as a cell-specific ligand exposed on
the outer surface of the liposome.

models, usually mice, rabbits, dogs, or pigs. The animal
model also can be used to determine the appropriate concentration range and route of administration. Such information
can then be used to determine useful doses and routes for
administration in humans.
Therapeutic efficacy and toxicity, e.g., ED 50 (the dose
therapeutically effective in 50% of the population) and LD 50
(the dose lethal to 50% of the population), can be determined
by standard pharmaceutical procedures in cell cultures or
experimental animals. The dose ratio of toxic to therapeutic
effects is the therapeutic index, and it can be expressed as the
ratio, LD 50/ED 50 .
Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell
culture assays and animal studies is used in formulating a
range of dosage for human use. The dosage contained in such
compositions is preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity. The
dosage varies within this range depending upon the dosage
form employed, sensitivity of the patient, and the route of
administration.
The exact dosage will be determined by the practitioner, in
light of factors related to the subject that requires treatment.
Dosage and administration are adjusted to provide sufficient
levels of the active ingredient or to maintain the desired effect.
Factors which can be taken into account include the severity
of the disease state, general health of the subject, age, weight,
and gender of the subject, diet, time and frequency of container and labeled for treatment of an indicated condition.
Such labeling would include amount, frequency, and method
of administration.
Normal dosage amounts can vary from 0.1 to 100,000
micrograms, up to a total dose of about 1 g, depending upon
the route of administration. Guidance as to particular dosages
and methods of delivery is provided in the literature and
generally available to practitioners in the art. Those skilled in
the art will employ different formulations for nucleotides than
for proteins or their inhibitors.
In any of the embodiments described above, any of the
pharmaceutical compositions of the invention can be administered in combination with other appropriate therapeutic
agents. Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art,
according to conventional pharmaceutical principles. The
combination of therapeutic agents can act synergistically to
effect the treatment or prevention of the various disorders
described above. Using this approach, one may be able to
achieve therapeutic efficacy with lower dosages of each
agent, thus reducing the potential for adverse side effects.
Any of the therapeutic methods described above can be
applied to any subject in need of such therapy, including, for
example, mammals such as dogs, cats, cows, horses, rabbits,
monkeys, and most preferably, humans.

Determination of a Therapeutically Effective Dose
The determination of a therapeutically effective dose is
well within the capability of those skilled in the art. A therapeutically effective dose refers to that amount of active ingredient which causes cytotoxicity of cancer cells in a subject
and/or metastatic behavior which occurs in the absence of the
therapeutically effective dose.
For any compound, the therapeutically effective dose can
be estimated initially either in cell culture assays or in animal
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Synethesis ofN-(3-Amino-propyl)-N'-anthracen-9ylmethyl-N'-ethyl-propane-1,3-diamine, Hydrochloride salt (7a)

65

Materials. Materials for Examples 1-16. Silica gel (32-63
µm) and chemical reagents were purchased from commercial
sources and used without further purification. All solvents
were distilled prior to use. All other reactions were carried out
under an N 2 atmosphere. 1 Hand 13 C spectra were recorded at

US 7,728,041 B2
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300 or 75 MHz, respectively. TLC solvent systems are listed
as volume percents and NH40H refers to concentrated aqueous NH40H.
A solution of BOC-protected 11 (700 mg, 1.28 mmole) was
dissolved in absolute ethanol (13 mL) and stirred at 0° C. for
10 minutes. A 4N HCl solution (22 mL) was added to the
reaction mixture dropwise and stirred at 0° C. for 20 minutes
and then at room temperature overnight. The solution was
concentrated in vacuo to give 7a as a yellow solid in 90%
yield. 1H NMR (D 20) o 8.23 (s, lH), 7.91 (m, 4H), 7.70 (m,
2H), 7.59 (m, 2H), 4.70 (s, 2H), 3.34 (m, 2H), 3.11 (m, 4H),
3.00 (t, 2H), 2.84 (t, 2H), 2.05 (q, 2H), 1.96 (m, 2H), 1.41 (m,
3H); 13 C NMR (D 20): o133.7, 133.1(3C),132.3 (2C), 130.7
(2C), 128.1 (2C), 125.0 (2C), 121.1 (2C), 52.1, 51.8, 47.3,
47.2, 39.3 (2C), 26.5, 23.5, 11.32. HRMS (FAB) calcd for
C 23 H31 Ny3HC1(M+H-3HC!t350.2591, Found 350.2588.

EXAMPLE4

5
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15

EXAMPLE2
Synethesis ofN-(4-Amino-butyl)-N'-anthracen-9ylmethyl-N'-ethyl-butane-1,4-diamine Hydrochloride
salt (7b)
A solution of the respective Boe-protected precursor (similar to molecule 11 but having a 4,4-triamine sequence; 140
mg, 0.26 mmole) was dissolved in absolute ethanol (2.28 mL)
and stirred at 0° C. for 10 minutes. A 4N HCl solution (3.64
mL) was added to the reaction mixture dropwise and stirred at
0° C. for 20 minutes and then at room temperature overnight.
The solution was co~centrated in vacuo to give 7b as a yellow
solid in 93% yield; H NMR (D 20) o 8.76 (s, lH), 8.23 (m,
4H), 7.78 (m, 2H), 7.68 (m, 2H), 5.33 (s, 2H), 3.43 (m, 2H),
3.19 (m, 2H), 3.04 (t, 2H), 3.00 (t, 2H), 2.83 (t, 2H), 1.74 (m,
6H), 1.47 (m, SH); 13 C NMR (CD30D): 0 133.0, 132.9,
132.6, 130.9, 129.4, 126.7, 124.3, 121.4, 53.4, 51.0, 40.1,
25.8, 24.7, 24.5, 22.3, 9.7. HRMS (FAB) calcdforC 25 H35 N 3
(M-Clt; 377.2831, Found 377.2831.

20

25

To a stirred solution of amine 9 (1 g, 3.02 mmol) in 25%
MeOH/CH 2Cl 2 (20 mL), was added a solution of 9-anthraldehyde 8 (0.519 g, 2.52 mmol) in 25% MeOH/CH 2Cl 2 (15
mL) under N 2. The mixture was stirred at room temperature
overnight until the imine formation was complete (monitored
by NMR). The solvent was removed in vacuo, the solid residue dissolved in 50% MeOH/CH 2Cl 2 (40 mL) and the solution cooled to 0° C. NaBH4 (7 .55 mmol) was added in small
portions to the solution and the mixture was stirred at rt
overnight. The solvent was removed in vacuo, the solid residue dissolved in CH 2Cl 2 (40 mL) and washed with Na2C03
solution (10% aq. 3x30 mL). The CH 2Cl 2 layer was dried
over anhydrous Na2S04, filtered and removed in vacuo to
give an oily residue. The oil was purified by flash column
chromatography (5% MeOH/CHCl 3) to yield the product 10
as a pale yellow thick oil (0.38 g, 75%), Rf=0.3 (5% MeOH/
CHC1 3); 1H NMR (CDC1 3) o 8.39 (s, lH), 8.34 (d, 2H), 7.99
(d, 2H), 7.53 (m, 2H), 7.46 (m, 2H), 4.70 (s, 2H), 3.18-3.24
(m, 4H), 3.06 (brt, 2H), 2.85 (brt, 2H), 1.77 (brq, 2H), 1.60
(br q, 2H), 1.44 (m, 18H); 13 C NMR (CDC1 3) o 156.1 (2C),
131.6, 130.3 (2C), 129.2 (2C), 127.2 (2C), 126.1(2C),125.0
(3C), 124.2 (2C), 79.7 (2C), 53.7, 48.0, 46.0, 45.3, 44.0, 37.6,
29.6, 28.7 (6C), 27.5. HRMS (FAB) m/z calcd. for
C31H43N304 (M+Hr 522.3326, found 522.3304.

Ethylbromide (EtBr, 508 mg, 4.66 mmol) was dissolved in
anhydrous acetonitrile and added to a stirring mixture of
compound 10 (805 mg, 1.55 mmol) and anhydrous K2C03
(644 mg, 4.66 mmol). The mixture was then stirred overnight
at 7 5° C. under a N 2 atmosphere. After the confirmation of the
disappearance of the 10 by TLC, the solution was concentrated under reduced pressure. The residue was dissolved in
CH 2Cl 2 (20 mL) and washed three times with aqueous
sodium carbonate. The organic layer was separated, dried
with anhydrous Na2S04, filtered and concentrated under
vacuum. Flash colunm chromatography of the residue gave
11 as a light yellow oil. Yield 80%; Rf=0.35 (3% MeOH/
CHC1 3); 1H NMR (CDC1 3) o 8.43 (d, 2H), 8.25 (s, lH), 7.86
(d, 2H), 7.43 (m, 2H), 7.37 (m, 2H), 4.34 (s, 2H), 2.78-2.92
(m, 4H), 2.64 (m, 4H), 2.36 (m, 2H), 1.21-1.48 (m, 23H), 1.16
(m, 2H); 13 C NMR (CDCl3) o155.7, 131.1(3C),131.0, 128.7
(2C), 127.0 (2C), 125.2 (2C), 124.8 (2C), 124.5 (2C), 78.9,
78.4, 53.4, 50.6, 50.0, 47.9, 45.3, 43.5, 37.1, 28.3 (6C), 26.5,
11.7. HRMS (FAB) m/z calcd. for C 33 H47N 30 4 (M+Ht
550.3639, found 550.3619.
EXAMPLE 5
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EXAMPLE3
Synethesis of {3-[(Anthracen-9-ylmethyl)-amino ]propyl}-(3-tert-butoxycarbonylamino-propyl)-carbamic acid tert-butyl ester (10)

Synethesis of [3-(Anthracen-9-ylmethyl-ethylamino )-propy l]-(3-tert-butoxycarbonylamino-propy1)-carbamic acid tert-butyl ester (11)
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Synethesis ofMethanesulfonic acid
3-(anthracen-9-ylmethyl-ethyl-amino)-propyl ester
(17)
To a solution of the alcohol 14b (216 mg, 0.74 mmol) and
triethylamine (0.31mL,2.21 mmol) inCH 2Cl 2 (40mL) at0°
C., methanesulfonyl chloride (253 mg, 2.21 mmol) was
added dropwise over 30 minutes under a N 2 atmosphere. The
reaction was stirred at 0° C. for 1 hour and slowly warmed to
room temperature and stirred overnight under N 2. The reaction was then cooled to 0° C. and a 4M NaOH solution (20
mL) was added slowly with vigorous stirring. The organic
phase was separated and washed with water (2x40 mL). The
organic phase was separated and dried over anhydrous
Na 2S04, filtered and concentrated to give the product 17 as a
clear oil (94%) that was used in the next step without further
purification. 17: Rf=0.54 (1% MeOH/CH 2Cl 2); 1H NMR
(CDC1 3) o 8.47 (d, 2H), 8.36 (s, lH), 7.98 (d, 2H), 7.52 (m,
2H), 7.47 (m, 2H), 4.43 (s, 2H, CH 2), 3.82 (t, 2H, OCH 2), 3.11
(s, 3H, CH 3), 2.70 (q, 2H, NCH 2), 2.51(t,2H, NCH 2), 1.66 (q,
2H, CH 2), 1.20 (t, 3H, CH 3).
EXAMPLE 6
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Synethesis 3-[3-(Anthracen-9-ylmethyl-ethylamino )-propylamino ]-propan-1-ol (18)
The mesylate 17 (384 mg, 1.04 mmol) and 3-amino-propanol (392 mg, 5.25 mmol) were dissolved in acetonitrile (20
mL). The mixture was then stirred at 75° C. under a N 2
atmosphere overnight. After the confirmation of the disappearance of the mesylate by TLC, the solution was concentrated under reduced pressure. The residue was dissolved in
CH 2Cl 2 (20 mL) and washed three times with aqueous
sodium carbonate. The organic layer was separated, dried
with anhydrous Na2S04, filtered and concentrated under
vacuum. Flash colunm chromatography of the residue gave
18 as a light yellow oil.Yield 65%; Rf=0.35 (1:6:83 NH40H:

US 7,728,041 B2
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MeOH:CH 2 Cl 2 ); 1H NMR (CDCl 3) o 8.32 (d, 2H), 8.23 (s,
lH), 7.83 (d, 2H), 7.37 (m, 2H), 7.30 (m, 2H), 4.28 (s, 2H),
3.48 (t, 2H), 2.S6 (q, 2H), 2.30 (t, 2H), 2.12 (t, 2H), 2.06 (t,
2H), 1.36 (q, 2H), 1.21 (q, 2H), 1.09 (t, 3H); 13 C NMR
(CDCl 3) o 131.3, 131.2, 130.S, 129.3, 129.0, 127.3, l2S.S,
12S.3, 124.8, 124.8, 63.8, S0.8, SO.S, 49.S, 48.3, 47.7, 30.S,
26.6, 11.7. HRMS (FAB) m/z calcd. forC 23 H30 N 2 0 (M+Ht
3Sl.2431; found 3Sl.2430.
EXAMPLE6

10
3.lS (t, 2H), 2.84 (t, 2H), 2.73 (t, 2H), 1.79 (m, 4H), 1.47 (t,

5

EXAMPLE 9
10

Synethesis ofN-Anthracen-9-ylmethyl-N'-(3-ethoxypropyl)-N-ethyl-propane-1,3-diamine (19)
The mesylate 17 (S84 mg, l .S7 mmol) and 3-ethoxypropylamine (649 mg, 6.30 mmol) were dissolved in acetonitrile
(30 mL). The mixture was then stirred at 7S° C. under a N 2
atmosphere overnight. After the confirmation of the disappearance of the mesylate by TLC, the solution was concentrated under reduced pressure. The residue was dissolved in
CH 2 Cl 2 (2S mL) and washed three times with aqueous
sodium carbonate. The organic layer was separated, dried
with anhydrous Na2 S04, filtered and concentrated under
vacuum. Flash colunm chromatography of the residue gave
19 as a light yellow oil. Yield 60%; Rf=0.3S (O.S:4:8S.S
NH40H:MeOH:CH 2 Cl 2 ); 1H NMR (CDCl 3) o 8.43 (d, 2H),
8.29 (s, lH), 7.89 (d, 2H), 7.40 (m, 4H), 4.38 (s, 2H), 3.3S (q,
2H), 3.2S (t, 2H), 2.62 (q, 2H), 2.44 (t, 2H), 2.27 (t, 2H), 2.23
(t, 2H), l.S4 (q, 2H), 1.41(q,2H), 1.14 (m, 6H); 13 C NMR
(CDCl 3) o 131.3, 131.2, 130.6, 128.9, 127.2, 12S.4, l2S.O,
124.7, 69.1, 66.0, S0.7, S0.6, 48.2, 47.S, 47.2, 30.1, 27.1, lS.4,
11.9.
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EXAMPLE 7
35

Synethesis ofN-Anthracen-9-ylmethyl-N'-(3-ethoxypropyl)-N-ethyl-propane-1,3-diamine, Hydrochloride salt (20)
A solution of compound 18 (200 mg, O.S7 mmole) was
dissolved in absolute ethanol (13 mL) and stirred at 0° C. for
10 minutes. A 4N HCI solution (22 mL) was added to the
reaction mixture dropwise and stirred at 0° C. for 20 minutes
and then at room temperature overnight. The solution was
concentrated in vacuo to give 20 as a yellow solid in 9S%
yield. 1H NMR (D 2 0) o 8.SO (s, lH), 8.06 (m, 4H), 7.73 (m,
2H), 7.62 (m, 2H), 4.98 (s, 2H), 3.64 (t, 2H), 3.39 (q, 2H), 3.13
(t, 2H), 2.90 (t, 2H), 2.76 (t, 2H), 1.79 (q, 2H), 1.44 (m, SH);
13
C NMR (D 2 0): o 133.8, 133.4, 132.4, 130.8, 128.3, 12S.1,
121.8, 61.4, S2.4, S2.l, S2.0, 48.0, 47.0, 30.S, 23.4, 11.3.
HRMS (FAB) calcd for C 23 H30N2 0.2HCI (M+H-2HCit
3Sl.2431, Found 3Sl.2428.

3H), l.lS (t, 3H); 13 C NMR (D 2 0): o 133.9, 133.S, 132.S,
130.9, 128.4, 12S.2, 122.1, 69.9, 69.3, S2.7, S2.4, S2.2, 48.1,
47.0, 28.2, 23.S, 17.0, 11.4. HRMS (FAB) calcd for
C 25 H34N 2 0.2HCI
(M+H-2HC!t
379.2749,
Found
379.2749.
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Synthesis ofN-{3-[3-(Anthracen-9-ylmethyl-ethylamino )-propy!amino ]-propyI}-acetamide (23)
A saturated sodium carbonate solution (20 mL) was added
to a vigorously stirred solution of7a (2SO mg, O.SS mmol) in
CH 2 Cl 2 (20 mL). The organic layer was separated and was
washed twice with saturated sodium carbonate. The combined organic layers were dried with anhydrous Na 2 S04,
filtered and concentrated to give the free amine 22 as a pale
yellow oil in 99% yield. 22: 1H NMR (CDCl 3) o8.48 (d, 2H),
8.38 (s, lH), 7.97 (d, 2H), 7.47 (m, 4H), 4.47 (s, 2H), 2.70 (q,
2H), 2.Sl (m, 4H), 2.29 (t, 2H), 2.17 (t, 2H), l.S6 (q, 2H), 1.24
(m, SH); 13 C NMR (CDCl3): 6 131.S, 131.4, 130.9, 129.1,
127.4, 12S.6, l2S.S, l2S.2, 124.9, S0.8, S0.7, 48.3, 47.8, 40.7,
33.7, 27.0, 12.0.
A mixture of compound 22 (190 mg, O.S4 mmol) and
anhydrous K 2 C03 (113 mg, 0.82 mmol) in anhydrous
CH 2 Cl 2 was stirred at 0° C. for 10 minutes. N-Acetoxysuccinimide (NHS ester, 60 mg, 0.38 mmol) was dissolved in dry
CH 2 Cl 2 and was added slowly to the above stirred solution at
0° C. under N 2 atmosphere. The mixture was then stirred for
30 minutes at 0° C. and then slowly allowed to come at room
temperature and stirred for 8 hrs. After the confirmation of the
disappearance of the ester by TLC in CH 2 Clihexane (7:3),
the solution was filtered and concentrated under reduced
pressure. The residue was dissolved in CH 2 Cl 2 (20 mL) and
washed three times with aqueous sodium carbonate. The
organic layer was separated, dried with anhydrous Na 2 S04,
filtered and concentrated under vacuum. Flash column chromatography of the residue gave 23 as a light yellow oil. Yield
67%; Rf=0.30 (7% MeOH: 1% NH40H: 82% CH 2 Cl 2 ); 1H
NMR (CDCl 3) o8.43 (d, 2H), 8.3S (s, lH), 7.9S (d, 2H), 7.23
(m, 4H), 6.84 (br t, lH), 4.43 (s, 2H), 3.0S (q, 2H), 2.71 (q,
2H), 2.43 (t, 2H), 2.20 (t, 2H), 2.09 (t, 2H), 2.78 (s, 3H), 2.48
(q, 2H), 1.21 (m, SH); 13 C NMR (CDCl3) 0 170.0, 131.4,
131.3, 130.6, 129.1, 127.S, 12S.7, 124.9, 124.9, S0.6, 48.1,
48.0, 48.0, 39.0, 28.2, 26.6, 23.4, 11.8. HRMS (FAB) m/z
calcd. for C 25 H33 N 30 (M+Ht 392.2701, found 392.2709.
EXAMPLE 10

50

Synthesis ofN-{3-[3-(Anthracen-9-ylmethyl-ethylamino )-propylamino ]-propyl }-acetamide, Hydrochloride salt (24)

EXAMPLES
55

Synthesis ofN-Anthracen-9-ylmethyl-N'-(3-ethoxypropyl)-N-ethyl-propane-1,3-diamine, Hydrochloride salt (21)
A solution of compound 19 (169 mg, OAS mmole) was
dissolved in absolute ethanol (13 mL) and stirred at 0° C. for
10 minutes. A 4N HCI solution (22 mL) was added to the
reaction mixture dropwise and stirred at 0° C. for 20 minutes
and then at room temperature overnight. The solution was
concentrated in vacuo to give 21 as a yellow solid in 9S%
yield. 1HNMR(D 2 0) o 8.SS (s, lH), 8.lO(m, 4H), 7.73 (m,
2H), 7.62 (m, 2H), S.12 (s, 2H), 3.S2 (m, 4H), 3.43 (q, 2H),

60

65

A solution of compound 23 (100 mg, 0.26 mmole) was
dissolved in absolute ethanol (13 mL) and stirred at 0° C. for
10 minutes. A 4N HCI solution (22 mL) was added to the
reaction mixture dropwise and stirred at 0° C. for 20 minutes
and then at room temperature overnight. The solution was
concentrated in vacuo to give 24 as a yellow solid in 96%
yield. 1H NMR (D 2 0) o 8.S9 (s, lH), 8.10 (m, 4H), 7.70 (m,
2H), 7.61 (m, 2H), S.13 (s, 2H), 3.41 (br m, 2H), 3.12 (br m,
4H), 2.79 (brm, 4H), 1.98 (s, 3H), 1.71(q,2H), 1.43 (m, SH);
13
C NMR (D 2 0): o 174.S, 131.3, 130.8, 129.8, 128.2, 12S.7,
122.S, 119.1, SO.O, 49.7, 49.4, 44.9, 44.1, 36.0, 2S.S, 21.9,
20.8, 8.7. HRMS (FAB) calcd for C 25 H33 N 30.2HCI (M+H2HCit 392.2701, Found 392.2702.

US 7,728,041 B2
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EXAMPLE 11

4.87 (s, 2H), 3.34 (brq, 2H), 3.14 (brt, 2H), 2.81(t,2H), 2.00
(q, 2H), 1.40 (t, 3H); 13 C NMR (D 2 0): o 133.8, 133.3 (3C),
132.4 (2C), 130.7 (2C), 128.2 (2C), 125.1 (2C), 121.5 (2C),
52.0, 51.9, 39.2 (2C), 24.5, 11.3. HRMS (FAB) calcd for
C 20 H 24N 2 .2HC1 (M+H-2HC!t 293.2012, Found 293.2009.

Synthesis of {3-[(Anthracen-9-ylmethyl)-amino ]propyl}-carbamic acid tert-butyl ester (12a)
5

To a stirred solution of mono-BOC protected 1,3-diamine
15b (1 g, 5.75 mmol) in 25% MeOH/CH 2 Cl 2 (20 mL), was
added a solution of 9-anthraldehyde 8 (0.99 g, 4.8 mmol) in
25% MeOH/CH 2 Cl 2 (15 mL) under N 2 . The mixture was
stirred at room temperature overnight until the imine formation was complete (monitored by NMR). The solvent was
removed in vacuo, the solid residue dissolved in 50% MeOH/
CH 2 Cl 2 (40 mL) and the solution cooled to 0° C. NaBH4
(14.42 mmol) was added in small portions to the solution and
the mixture was stirred at rt overnight. The solvent was
removed in vacuo, the solid residue dissolved in CH 2 Cl 2 ( 40
mL) and washed with Na 2 C0 3 solution (10% aq. 3x30 mL).
The CH 2 Cl 2 layer was dried over anhydrous Na 2 S04 , filtered
and removed in vacuo to give an oily residue. The oil was
purified by flash colunm chromatography (5% MeOH/
CHC1 3 ) to yield the product 12a as a pale-yellow, thick oil
(75% ). Rf=0.3 (5% MeOH/CHC1 3 ); 1 H NMR (CDC1 3 ) o8.20
(m, 3H), 7.85 (d, 2H), 7.43 (m, 2H), 7.36 (m, 2H), 5.32 (t, lH),
4.52 (s, 2H), 3.10 (q, 2H), 2.77 (t, 2H), 1.56 (q, 2H), 1.39 (s,
9H); 13 C NMR (CDC1 3 ) o 156.0, 131.3 (2C), 130.1 (2C),
129.0 (2C), 127.0 (2C), 125.9 (2C), 124.8 (2C), 124.0 (2C),
78.7 (2C), 48.5, 45.8, 39.4, 29.9, 28.5. HRMS (FAB) rn/z
calcd. for C 23 H 28 N 2 0 2 (M+Ht 365.2224; found 365.2208.
EXAMPLE 12

EXAMPLE 14
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To a stirred solution of3-amino -1-propanol, 15a (0.87 g,
11.65 mmol) in 25% MeOH/CH 2 Cl 2 (20 mL), was added a
solution of aldehyde 8 (2.00 g, 9.7 mmol) in 25% MeOH/
CH 2 Cl 2 (15 mL) under N 2 . The mixture was stirred at room
temperature overnight until the imine formation was complete (monitored by NMR). The solvent was removed in
vacuo, the solid residue dissolved in 50% MeOH/CH 2 Cl 2 ( 40
mL) and the solution was cooled to 0° C. NaBH4 (29.1 mmol)
was added in small portions to the solution and the mixture
was stirred at rt overnight. The solvent was removed in vacuo,
the solid residue dissolved in CH 2 Cl 2 (40 mL) and washed
with 10% aq. Na 2 C0 3 solution (3x30 mL). The CH 2 Cl 2 layer
was separated, dried over anhydrous Na 2 S04 , filtered and
removed in vacuo to give an oily residue. The oil was purified
by flash colunm chromatography (6% MeOH/CHCl 3 ) to
yield the product 14a as a pale yellow thick oil (78%), Rf=0.3
(6% MeOH/CHCl 3 ); 1 H NMR (CDC1 3 ) o 8.39 (s, lH), 8.27
(d, 2H), 7.99 (d, 2H), 7.52 (m, 2H), 7.45 (m, 2H), 4.71(s,2H),
3.79 (t, 2H), 3.09 (t, 2H), 1.74 (q, 2H).
EXAMPLE 15

Synthesis of [3-(Anthracen-9-ylmethyl-ethylamino )-propyl]-carbamic acid tert-butyl ester (12b)
Bromoethane (489 mg, 4.48 mmol) was dissolved in anhydrous acetonitrile and was added to the stirring mixture of
compound 12a (545 mg, 1.5 mmol) and anhydrous K 2 C0 3
(620 mg, 4.48 mmol). The mixture was then stirred at 75° C.
under a N 2 atmosphere overnight. After the confirmation of
the disappearance of the 12a by TLC, the solution was concentrated under reduced pressure. The residue was dissolved
in CH 2 Cl 2 (20 mL) and washed three times with aqueous
sodium carbonate. The organic layer was separated, dried
with anhydrous Na2 S04 , filtered and concentrated under
vacuum. Flash colunm chromatography of the residue gave
12b as a light yellow oil. Yield 80%; Rf=0.35 (3% MeOH/
CHC1 3 ); 1 H NMR (CDC1 3 ) o 8.39 (d, 2H), 8.30 (s, lH), 7.90
(d, 2H), 7.40 (m, 4H), 4.54 (br t, lH), 4.37 (s, 2H), 2.74 (q,
2H), 2.60 (q, 2H), 2.39 (t, 2H), 1.44 (q, 2H), 1.31 (m, 9H),
1.12 (t, 3H); 13 C NMR (CDC1 3 ) o 155.7, 131.3 (2C), 131.2
(2C), 130.4 (2C), 129.0 (2C), 127.5 (2C), 125.7 (2C), 124.8
(2C), 78.3, 50.6, 50.5, 47.7, 39.1, 28.6 (3C), 26.6, 11.8.
HRMS (FAB)m/zcalcd. forC 25 H32N 2 0 2 (M+Ht 393.2537;
found 393.2523.

Synthesis of
3-[ (Anthracen-9-ylmethyl)-amino]-propan-1-ol, 14a
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Synthesis of
3-(Anthracen-9-ylmethyl-ethyl-amino )-propan-1-ol,
14b
Bromoethane (616 mg, 5 .65 mmol) was dissolved in anhydrous acetonitrile and was added to the stirring mixture of
compound 14a (500 mg, 1.9 mmol) and anhydrous K 2 C0 3
(781 mg, 5.7 mmol). The mixture was then stirred overnight
at 75° C. under a N 2 atmosphere. After confirmation of the
disappearance of 14a by TLC, the solution was concentrated
under reduced pressure. The residue was dissolved in CH 2 Cl 2
(20 mL) and washed three times with aqueous sodium carbonate. The organic layer was separated, dried with anhydrous N a 2 SO4 , filtered and concentrated under vacuum. Flash
colunm chromatography of the residue gave 14b as a light
yellow oil. Yield 82%; Rf=0.35 (3% MeOH/CHCl 3 ); 1 H
NMR (CDC1 3 ) o 8.28 (m, 3H), 7.86 (d, 2H), 7.44 (m, 2H),
7.36 (m, 2H), 4.29 (s, 2H), 3.15 (t, 2H), 2.65 (q, 2H), 2.52 (t,
2H), 1.43 (q, 2H), 1.16 (t, 3H); 13 C NMR (CDC1 3 ) o 131.2,
131.1, 129.3, 129.0, 127.6, 125.8, 124.8, 124.4, 63.4, 52.6,
50.5, 47.7, 28.1, 11.6. HRMS (FAB) rn/z calcd. for
C20H23NO (M+Hr 294.1852; found294.1859.

EXAMPLE 13
EXAMPLE 16
Synthesis ofN 1 -Anthracen-9-ylmethyl-N 1 -ethylpropane-l,3-diamine, Hydrochloride salt (12c)
A solution of 12b (400 mg, 1.02 mmole) was dissolved in
absolute ethanol (13 mL) and stirred at 0° C. for 10 minutes.
A 4N HCl solution (22 mL) was added to the reaction mixture
dropwise and stirred at 0° C. for 20 minutes and then at room
temperature overnight. The solution was concentrated in
vacuo to give 12c as a yellow solid in 90% yield. 1 H NMR
(D 2 0) o8.42 (s, lH), 8.0 (m, 4H), 7.71(m,2H), 7.61(m,2H),

60

Synthesis of
Nl-Anthracen-9-ylmethyl-propane-1,3-diamine,
Hydrochloride salt (16)

65

A solution of 12a (200 mg, 0.51 mmole) was dissolved in
absolute ethanol (6 mL) and stirred at 0° C. for 10 minutes. A
4N HCl solution (10 mL) was added to the reaction mixture
dropwise and stirred at 0° C. for 20 minutes and then at room
temperature overnight. The solution was concentrated in

US 7,728,041 B2
13

14

vacuo to give 16 as a yellow solid in 90% yield. 1 H NMR
(CD 3 0D) o 8.69 (s, lH), 8.39 (d, 2H), 8.15 (d, 2H), 7.74 (m,
2H), 7.60 (m, 2H), 5.33 (s, 2H), 3.45 (t, 2H), 3.12 (t, 2H), 2.23
(q, 4H); 13 C NMR (CD 3 0D): o6 132.6, 132.0, 131.6, 130.6,
129.0, 126.7, 124.0, 122.5, 46.6, 44.6, 38.1, 25.4. HRMS
(FAB) calcd for C 18 H 20 N 2 .2HCI (M+H-2HCit 265.1699,
Found 265.1704.

shown in Table 2, all of the derivatives gave medium to high
levels of inhibition in the assay, except 4b and 7b. In this
regard, most of the new materials provided similar inhibition
as 4a.
Note: the disc assay itselfis binary. The tested compound is
either as good as or worse than 4a. Compounds that are better
than 4a will only give the same maximal response (90-100%
inhibition). Future work will be necessary to see which of the
most active compounds (6a, 6b, 7a, 12c, 13b, 16, 20, 21, and
24) are best in vivo in terms of slowing the spread of cancers
(anti-metastatic activity).
Fly Stocks: 20 female and 5 male wild type Oregon variant
of Drosophila melanogaster interbred in blue food medium
for 24 hours then flies are removed. Third instar wall-crawling larvae collected then dissected on the sixth day. Flies kept
in 25° C. incubation chamber.
Blue Food Preparation: Standard corn meal medium
heated then mixed completely with aqueous 1% Bromophenol Blue. The food medium is cooled for one day or more
before use.
Dissection Medium: Ringer's Buffer with 10 uL 0.1%
BSA. Ringer's Medium consists of 130 mM NaCl, 5 mM
KC!, 1.5 mM CaCl 2 -2H 2 0. Stored at room temperature (23°
C.), BSA added before dissection.
Cultivation Medium: Minimal Robb's Medium with 10 uL
0.1 % BSA. Minimal Robb's Medium consists of 40 mMKCI,
0.4 mM KH 2 P04 , 40 mM NaCl, 0.4 mM NaH 2 P04 -7H 2 0,
1.2 mM MgS04 - 7H 2 0, 1.2 mM MgCl 2 -6 H 2 0, 1 mM

5

EXAMPLE 17
10

Biological evaluation of polyamine derivatives
In terms of Table 1, L1210 cells are mouse leukemia cells
and are the gold standard in terms of evaluating polyamine
cytotoxicity data due to a plethora of prior data in this cell line
for other polyamine structures. Clearly 7a was similar in all
respects to 4a (Table 1). The fact that similar alterations in the
structure of 7a and 4a gave the same biological response
suggests that they are hitting the same biological target. Low
IC 50 values in Table 1 suggest greater cytotoxicity of the drug.
The lower the K, value, the higher the affinity of the drug for
the polyamine transporter (PAT) on the cell surface. Chinese
hamster ovary (CHO) cells and a mutant line without an
active PAT (CHO-MG) also evaluated the PAT selectivity of
these drugs. High (CHO-MG/CHO) IC 50 ratios suggest a
highly selective PAT substrate. Inspection ofTable 1 suggests
that 7 a is an effective mimic of 4a (both have low IC 50 values),
but does not use the PAT for cellular entry (both have low
CHO-MG/CHO IC 50 ratio).
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TABLE 1
Biological evaluation ofpolyamine derivatives in L1210. CHO and CHO-MG cells.a

Compd (tether)
4a: dihydroMotu (3 ,3)
4b: dihydroMotu (4,4)
6a: Ant-methyl (3,3)
6b: Ant-methyl (4,4)
6c: Ant-ethyl (4,4)
6d: Ant-propyl (4,4)
7a: N 1-ethyl-N 1-Antmethyl (3,3)
7b: N 1-ethyl-N 1 -Antmethyl (4,4)

L1210
IC 50 inµM
3.0
18.5
1.8
0.30
3.5
76.3
2.2

(±0.5)
(±2.9)
(±0.4)
(±0.04)
(±0.7)
(±4.8)
(±0.1)

22.2 (±1.2)

L1210
K, value (µM)
9.9
6.2
33.4
1.8
1.6
1.1
23.5

Ref

(±0.5)
(±0.5)
(±2.6)
(±0.1)
(±0.1)
(±0.1)
(±0.9)

24.4 (±1.5)

CHO-MG
IC 50 inµM
10.0
28.2
3.4
66.7
33.5
130.8
4.0

(±2.6)
(±5.6)
(±0.5)
(±4.1)
(±7.1)
(±5.5)
(±0.3)

21.9 (±0.9)

CHO
IC 50 inµM
10.5
30.0
1.9
0.45
9.8
130.1
5.3

(±1.6)
(±4.1)
(±0.4)
(±0.10)
(±1.1)
(±7.1)
(±0.4)

1.8
148
3.4
0.8

22.2 (±0.7)

aDefinitions used in Table 1, colunm 1: Ant~ anthracen-9-yl, dihydroMotu ~ dihydromotuporamine; column 4:
Ref denotes the reference number in which the data was originally reported. A blank in the Ref column denotes
new data. Cells were incubated for 48 h with the respective conjugate.
bThe IC 50 ratio denotes the (CHO-MG/CHO) IC 50 ratio, a measure of PAT selectivity.

EXAMPLE 18
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Inhibition ofMotuporamine Mimic Agents
DihydroMotuporamine C, 4a, was used to develop an
imaginal disc assay in Drosophila flies. The imaginal leg
discs were collected by microscopic dissection from maggots. The assay reproducibly showed that (at 18 µM) 4a gave
very high inhibition (~87%) of development of the imaginal
disc (Table 2). Inhibition was measured as failure of the disc
to fully develop into a fly leg after 15 hr of incubation in
Robb's growth medium. This presumably occurs by overactivation of Rho, an important signaling pathway in development. Hyper-stimulation ofthis pathway is sufficient to block
development of the fly leg.
Using this concentration (18 µM) the panel of mimics were
assayed (4, 6a, 6b, 7a, 7b, 12c, 13b, 16, 20, 21, and 24). As

55
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CaCl 2 -2 H 2 0, 10 mM Glucose, 0.2 mM L-asparagine, 4.0
mM L-glutamine, 0.16 mM Glycine, 0.64 mM L-leucine,
0.32 mM L-proline, 0.16 mM R-Serine, 0.64 mM L-valine.
Storedat-25° C. One day before dissection, aliquot defrosted
in 4° C. Add BSA then warmed to room temperature (23 ° C.)
before dissection.
0.1% BSA: 0.1 g BSA fraction V (Sigma#A-9647) in 10
mL distilled H 2 0. Stored at 4° C.
Developmental Hormone: 1 mg 20-hydroxyecdysone
(Sigma #H-5142) in 1mL100% Ethanol. Stored at -25° C.
Before use, stock is diluted 1Ox (1 mL added to 9 mL of 100%
Ethanol). 10 µL of diluted 20-hydroxyecdysone is added to
culture.
Dissection Procedures: Third instar larvae are removed
from cultivation bottle with a wetted brush and washed in
dH 2 0 to remove food medium clinging to larvae. The cleaned
larvae are dissected in Ringer's Medium using forceps. The

US 7,728,041 B2
15

16

imaginal discs are washed in fresh Ringer's Medium, and
then cultivated with 1 mL of Robb's Medium in 12-well
culture plate. Each culture well should have 30-40 imaginal
discs.
Culturing Procedures: In a larger container, place the
12-well culture plate on a moist towel, then seal the large
container. Cultivate at 25° C. for 15 hours. Evaluation: Three
categories will be used to grade the eversion of each imaginal
disc. Full Eversion-the leg is fully extended from the disc.
Partial Eversion-the leg is protruding from the epithelial.
No Eversion-no sign of any protrusion.

of Formula I, or a pharmaceutically acceptable salt thereof,
and a pharmaceutically acceptable carrier, wherein Formula I
JS:

Formula!

10

TABLE2
Eversion Inhibition by new compounds at
18 µM in an Imaginal Disc Assay"

Compound
4a (Motu 3,3)
4b (Motu 4,4)
6a (Ant 3,3)
6b (Ant4,4)
7a (AntNEt 3,3)
7b (AntNEt4,4)
12c (AntNEtDiamine 3)
13b (Ant Diamine 4)
16 (Ant Diamine 3)
20 (Ant NEt aminoalcohol 3,3)
21 (AntNEt amino ether 3 ,3)
24 (AntNEt acetamide 3,3)

15

% Inhibition

87
0
60
97
95
79
91
92
38
36
58

aThe error is typically near 10-15% for this type of developmental measurement.

While various embodiments of the present invention have
been shown and described herein, it will be obvious that such
embodiments are provided by way of example only. Numerous variations, changes and substitutions may be made without departing from the invention herein. Accordingly, it is
intended that the invention be limited only by the spirit and
scope of the appended claims. The teachings of all references
cited herein are incorporated in their entirety to the extent not
inconsistent with the teachings herein.
What is claimed is:
1. A pharmaceutical composition cytotoxic to cancer cells
wherein said composition comprises one or more compounds
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wherein R is anthracen-9-ylmethyl;
R 1 is ethyl;
R 2 is hydrogen, or BOC;
R3 is NH 2 or NHBOC; and
x=l-16 and y=l-16.
2. The composition of claim 1, wherein said composition
comprises one or more compounds of Formula I wherein:
R=anthracen-9-ylmethyl, R 1 =ethyl, R 2 =H, R3 =NH2, x=3,
andy=3;
R=anthracen-9-ylmethyl, R 1 =ethyl, R 2 =H, R3 =NH2, x=4,
andy=4;
R=anthracen-9-ylmethyl,
R 1 =ethyl,
R3 =NHBOC, x=3, and y=3; or
R=anthracen-9-ylmethyl,
R 1 =ethyl,
R3 =NHBOC, x=4, and y=4.
3. A method of killing cancer cells in a patient in need
thereof comprising administering one or more compounds
according to Formula I or II, or a pharmaceutically acceptable
salt thereof, effective to kill cancer cells in said patient,
wherein Formula I is:

Formula!
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wherein R is anthracen-9-ylmethyl;
R 1 is ethyl;
R 2 is hydrogen or BOC;
R3 is NH 2 or NHBOC; and
x=l-16 and y=l-16.

* * * * *

